Real-world evidence evaluation of LDL-C in hospitalized patients: a population-based observational study in the timeframe 2021-2022.
Cardiovascular risk
Frail
Inpatients
LDL cholesterol
Lipid-lowering therapies
Real-world evidence
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
10
05
2024
accepted:
17
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
European registries and retrospective cohort studies have highlighted the failure to achieve low-density lipoprotein-cholesterol (LDL-C) targets in many very high-risk patients. Hospitalized patients are often frail, and frailty is associated with all-cause and cardiovascular mortality. The aim of this study is to evaluate LDL-C levels in a real-world inpatient setting, identifying cardiovascular risk categories and highlighting treatment gaps in the implementation of LDL-C management. This retrospective, observational study included all adult patients admitted to an Italian hospital between 2021 and 2022 with available LDL-C values during hospitalization. Disease-related real-world data were collected from Hospital Information System using automated data extraction strategies and through the implementation of a patient-centered data repository (the Dyslipidemia Data Mart). We performed assessment of cardiovascular risk profiles, LDL-C target achievement according to the 2019 ESC/EAS guidelines, and use of lipid-lowering therapies (LLT). 13,834 patients were included: 17.15%, 13.72%, 16.82% and 49.76% were low (L), moderate (M), high (H) and very high-risk (VH) patients, respectively. The percentage of on-target patients was progressively lower towards the worst categories (78.79% in L, 58.38% in M, 33.3% in H and 21.37% in VH). Among LLT treated patients, 28.48% were on-target in VH category, 47.60% in H, 69.12% in M and 68.47% in L. We also analyzed the impact of monotherapies and combination therapies on target achievement. We found relevant gaps in LDL-C management in the population of inpatients, especially in the VH category. Future efforts should be aimed at reducing cardiovascular risk in these subjects.
Identifiants
pubmed: 39049007
doi: 10.1186/s12944-024-02221-x
pii: 10.1186/s12944-024-02221-x
doi:
Substances chimiques
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
224Informations de copyright
© 2024. The Author(s).
Références
Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716–99. https://doi.org/10.1093/eurheartj/ehab892
doi: 10.1093/eurheartj/ehab892
pubmed: 35016208
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689–700. https://doi.org/10.1038/s41569-021-00541-4 . Epub 2021 Apr 8. PMID: 33833450.
doi: 10.1038/s41569-021-00541-4
pubmed: 33833450
Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25. https://doi.org/10.1016/S0140-6736(08)60104-X
doi: 10.1016/S0140-6736(08)60104-X
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014
doi: 10.1016/j.atherosclerosis.2019.08.014
Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–35. https://doi.org/10.1177/2047487318825350
doi: 10.1177/2047487318825350
pubmed: 30739508
Morieri ML, Avogaro A, Fadini GP. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics. Cardiovasc Diabetol. 2020;19. https://doi.org/10.1186/s12933-020-01164-8
Ray KK, Haq I, Bilitou A, Aguilar C, Arca M, et al. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus. 2021;43:24–30. https://doi.org/10.1016/j.athplu.2021.08.003
doi: 10.1016/j.athplu.2021.08.003
pubmed: 36644508
pmcid: 9833224
Veronese N, Custodero C, Cella A, et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: a systematic review and meta-analysis. Ageing Res Rev. 2021;72. https://doi.org/10.1016/j.arr.2021.101498
Bagshaw SM, Stelfox HT, McDermid RC, et al. Association between frailty and short- and long-term outcomes among critically ill patients: a multicentre prospective cohort study. CMAJ Can Med Association J. 2014;186. https://doi.org/10.1503/cmaj.130639
White HD, Westerhout CM, Alexander KP, Winters KJ, Cyr DD, et al. Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: insights from the TaRgeted platelet inhibition to cLarify the optimal strateGy to medicallY manage acute coronary syndromes (TRILOGY ACS) trial. Eur Heart J Acute Cardiovasc Care. 2016;5:231–42. https://doi.org/10.1177/2048872615581502
doi: 10.1177/2048872615581502
pubmed: 25897147
Fan J, Yu C, Guo Y, Bian Z, Sun Z, et al. Frailty index and all-cause and cause-specific mortality in Chinese adults: a prospective cohort study. Lancet Public Health. 2020;5:e650–60. https://doi.org/10.1016/S2468-2667(20)30113-4
doi: 10.1016/S2468-2667(20)30113-4
pubmed: 33271078
pmcid: 7708389
Mamas MA, Fath-Ordoubadi F, Danzi GB, Spaepen E, Kwok CS, et al. Prevalence and impact of co-morbidity burden as defined by the charlson co-morbidity index on 30-day and 1- and 5-year outcomes after coronary stent implantation (from the Nobori-2 study). Am J Cardiol. 2015;116:364–71. Epub 2015 May 8.
doi: 10.1016/j.amjcard.2015.04.047
pubmed: 26037294
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. 1972.
Damiani A, Masciocchi C, Lenkowicz J, et al. Building an artificial intelligence laboratory based on real world data: the experience of Gemelli generator. Front Comput Sci. 2021;3. https://doi.org/10.3389/fcomp.2021.768266
Hodkinson A, Tsimpida D, Kontopantelis E, et al. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022. https://doi.org/10.1136/bmj-2021-067731
doi: 10.1136/bmj-2021-067731
pubmed: 36450393
pmcid: 9472104
Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. https://doi.org/10.1016/s0195-668x(03)00114-3
doi: 10.1016/s0195-668x(03)00114-3
pubmed: 12788299
Garies S, Cummings M, Quan H, et al. Methods to improve the quality of smoking records in a primary care EMR database: exploring multiple imputation and pattern-matching algorithms. BMC Med Inf Decis Mak. 2020;20. https://doi.org/10.1186/s12911-020-1068-5
Ray KK, Molemans B, Marieke Schoonen W, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DAVINCI study. Eur J Prev Cardiol. 2021;28:1279–89. https://doi.org/10.1093/eurjpc/zwaa047
doi: 10.1093/eurjpc/zwaa047
pubmed: 33580789
Limpawattana P, Khammak C, Manjavong M, et al. Frailty as a predictor of hospitalization and low quality of life in geriatric patients at an internal medicine outpatient clinic: a cross-sectional study. Geriatr (Switzerland). 2022;7. https://doi.org/10.3390/geriatrics7050089
Jędrzejczyk M, Foryś W, Czapla M, et al. Relationship between multimorbidity and disability in elderly patients with coexisting frailty syndrome. Int J Environ Res Public Health. 2022;19. https://doi.org/10.3390/ijerph19063461
Morieri ML, Lamacchia O, Manzato E, et al. Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes. Cardiovasc Diabetol. 2022;21. https://doi.org/10.1186/s12933-022-01495-8
Yun SJ, Jeong IK, Cha JH, et al. Current status of low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes mellitus in Korea compared with recent guidelines. Diabetes Metab J. 2022;46:464–75.
doi: 10.4093/dmj.2021.0088
pmcid: 9171162
Van Leeuwen HJ, Heezius ECJM, Dallinga GM, van Strijp JA, Verhoef J, et al. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31:1359–66. https://doi.org/10.1097/01.CCM.0000059724.08290.51
doi: 10.1097/01.CCM.0000059724.08290.51
pubmed: 12771603
da Silva PM, Aguiar C, Morais J. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: data from the DISGEN-LIPID study. Rev Port Cardiol. 2019;38:559–69.
doi: 10.1016/j.repc.2019.02.009
pubmed: 31706732
Lee SJ, Joo JH, Park S, Kim C, Choi DW, et al. Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2023;82:401–10. https://doi.org/10.1016/j.jacc.2023.05.042
doi: 10.1016/j.jacc.2023.05.042
pubmed: 37495276
Masana L, Ibarretxe D, Plana N. Reasons why combination therapy should be the new standard of care to achieve the LDL-cholesterol targets: lipid-lowering combination therapy. Curr Cardiol Rep. 2020;22. https://doi.org/10.1007/s11886-020-01326-w
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2022;80:1366–418.
doi: 10.1016/j.jacc.2022.07.006
pubmed: 36031461
Moffa S, Mezza T, Ferraro PM, et al. Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study. Front Endocrinol (Lausanne). 2023;14. https://doi.org/10.3389/fendo.2023.1124116